Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Second proof of concept clinical trial of M-281

Trial Profile

Second proof of concept clinical trial of M-281

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nipocalimab (Primary)
  • Indications Haemolytic disease of newborn
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 07 Feb 2019 According to a Momenta Pharmaceuticals media release, the company now look forward for opening sites and enrolling patients.
    • 04 Oct 2018 According to a Momenta Pharmaceuticals media release, the company will host a live webcast of its R and D day on 11 Oct 2018, which will include a presentation of indications for the planned phase 2 proof of concept studies (this and other 292041).
    • 09 Aug 2018 According to a Momenta Pharmaceuticals media release, this trial is expected to initiate in the fourth quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top